MARKET

BPMC

BPMC

Blueprint
NASDAQ

Real-time Quotes | Nasdaq Last Sale

98.22
+2.13
+2.22%
After Hours: 98.22 0 0.00% 16:52 02/26 EST
OPEN
96.90
PREV CLOSE
96.09
HIGH
99.17
LOW
94.03
VOLUME
455.64K
TURNOVER
--
52 WEEK HIGH
125.61
52 WEEK LOW
43.29
MARKET CAP
5.69B
P/E (TTM)
18.70
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
15 Fastest Growing Biotech Companies in the US
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the ...
Insider Monkey · 23h ago
Fibrodysplasia Ossificans Progressiva (FOP) - Pipeline Insight, 2020
Feb 26, 2021 (Heraldkeepers) -- DelveInsight's, "Fibrodysplasia Ossificans Progressiva (FOP) - Pipeline Insight, 2020," report provides comprehensive...
Heraldkeepers · 2d ago
Fibroblast Growth Factor Receptor 4 Market Size, Growth, Share 2021 Global, Trends, Global Industry Key Players, Regional Forecast To 2026
Feb 22, 2021 (The Expresswire) -- Global Fibroblast Growth Factor Receptor 4 Market 2021 industry research report gives Advancement strategies and plans are...
The Express Wire · 5d ago
Gastrointestinal Stromal Tumor (GIST) Drug Market Size, Share, Growth 2021 with Forecast,Global Organizations, Top Vendors, Industry Research,Market and End User By 2026
Feb 22, 2021 (The Expresswire) -- Global Gastrointestinal Stromal Tumor (GIST) Drug Market 2021 industry research report gives Advancement strategies and...
The Express Wire · 5d ago
Analysts Are Bullish on Top Healthcare Stocks: Blueprint Medicines (BPMC), Exact Sciences (EXAS)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC), Exact Sciences (EXAS) and
SmarterAnalyst · 02/19 09:04
Global Fibroblast Growth Factor Receptor 4 Market Size 2021-2026 With Top Countries Data Industry Price Trend, Size Estimation, Business Growth, Report Latest Research, Business Analysis and Forecast Analysis Research | With Covid 19 Analysis
Feb 19, 2021 (The Expresswire) -- “Fibroblast Growth Factor Receptor 4 Market” Report (2021-2026) offers a learned and top to bottom investigation on the...
The Express Wire · 02/19 05:13
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), Henry Schein (HSIC) and Immunovant (IMVT)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC), Henry Schein (HSIC) and
SmarterAnalyst · 02/18 17:55
Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line
Zacks.com · 02/18 15:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BPMC. Analyze the recent business situations of Blueprint through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BPMC stock price target is 117.29 with a high estimate of 152.00 and a low estimate of 81.00.
EPS
Institutional Holdings
Institutions: 418
Institutional Holdings: 60.61M
% Owned: 104.57%
Shares Outstanding: 57.96M
TypeInstitutionsShares
Increased
72
3.26M
New
93
2.39M
Decreased
101
5.51M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
Daniel Lynch
President
Fouad Namouni
Chief Executive Officer/Director
Jeffrey Albers
Executive Vice President
Tracey Mccain
Chief Financial Officer
Michael Landsittel
Chief Operating Officer
Kathryn Haviland
Chief Human Resource Officer
Debra Durso-Bumpus
Executive Vice President
Anthony Boral
Senior Vice President
Christopher Murray
Chief Scientific Officer
Marion Dorsch
Chief Compliance Officer
Tracey McCain
Vice President/Controller
Ariel Hurley
Other
Becker Hewes
Other
Christina Rossi
Director
Alexis Borisy
Independent Director
Lonnel Coats
Independent Director
George Demetri
Independent Director
Mark Goldberg
Independent Director
Nicholas Lydon
Independent Director
Charles Rowland
Independent Director
Lynn Seely
  • Dividends
  • Splits
  • Insider Activity
No Data
About BPMC
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Webull offers kinds of Blueprint Medicines Corp stock information, including NASDAQ:BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.